TFDA (Taiwan)

TFDA (Taiwan Food and Drug Administration, 衛生福利部食品藥物管理署) is Taiwan's national regulatory authority for foods, drugs, medical devices, cosmetics + controlled substances. TFDA is an administrative agency under Taiwan's Ministry of Health and Welfare (MOHW / 衛生福利部), established 1 January 2010 by the merger of four predecessor MOHW agencies (Bureau of Food Safety, Bureau of Pharmaceutical Affairs, Bureau of Food and Drug Analysis + Bureau of Controlled Drugs). TFDA's headquarters is in Nangang District, Taipei + the agency has approximately 700 staff with regional offices supporting inspection + market surveillance.

The TFDA ecosystem includes:

• Division of Medicinal Products — pharmaceutical + biological + biosimilar registration, clinical-trial authorisation + GMP inspection programme management.
• Division of Medical Devices and Cosmetics — medical device + IVD + cosmetic registration + QMS evaluation + market surveillance.
• Division of Food Safety — food safety, food establishment registration + food import controls.
• Division of Controlled Drugs — narcotic + psychotropic substance regulation + import / export licensing.
• Division of Research and Analysis — TFDA central reference laboratory + analytical method development.
• Office of Risk Management — pharmacovigilance + medical-device vigilance + recall coordination.
• Office of International Affairs — international engagement (ICH, PIC/S, IMDRF, APEC, MDSAP) + bilateral MoUs.
• National Center for Drug Evaluation (財團法人醫藥品查驗中心 / CDE) — TFDA-affiliated review entity; analogous to PMDA's scientific arm; conducts most of TFDA's scientific review work for drugs + biologics + medical devices.

Legal foundations are the Pharmaceutical Affairs Act (藥事法 — substantially amended 2018 + 2020 + 2022 to align with global pharmaceutical regulatory frameworks), the Medical Devices Act (醫療器材管理法 — enacted May 2020 + effective May 2021, separated from the Pharmaceutical Affairs Act to provide modern medical-device regulatory framework substantively aligned with EU MDR + FDA QSR), the Act of Governing Food Safety and Sanitation, the Controlled Drugs Act, the Cosmetic Hygiene and Safety Act + a substantial body of MOHW Regulations + TFDA Guidelines + Notifications.

TFDA is a PIC/S Member since January 2013 (the first PIC/S Member in the Greater China region, predating both NMPA — which is not a PIC/S Member — + HKDH), an ICH Regulatory Member since June 2018 (the fifth Asian regulator after PMDA + MFDS + Singapore HSA + with full Member voting rights since June 2018), an IMDRF Affiliate Member, an MDSAP Affiliate Member (with progressing recognition for Taiwanese device QMS purposes), an APEC Regulatory Harmonization Steering Committee (RHSC) participant + a member of the Asian Harmonization Working Party (AHWP) for medical-device harmonisation.

TFDA's Reliance Pathway (信賴審查) is the agency's flagship work-sharing mechanism, established to leverage TFDA-designated reference regulator assessments + accelerate Taiwanese market access. The pathway has substantially shaped Taiwan's regulatory landscape since its formalisation + has been progressively expanded since TFDA's ICH Regulatory Membership in 2018.

• Designated reference regulators — FDA, EMA (centralised procedure), EU national authorities (typically MHRA, BfArM, ANSM, AIFA, AEMPS), MHRA, Health Canada, TGA, Swissmedic, PMDA + MFDS; periodically reviewed by TFDA.
• Reduced clock — substantially shorter than the standard 360 wd New Drug Application clock; specific timing depends on the reference-regulator package quality + Taiwan-specific assessment scope.
• Full reference-regulator dossier required — applicants provide the full assessment report, product information + supporting documentation from the reference regulator; TFDA + CDE conduct a Taiwan-specific overlay assessment focused on Taiwan labelling, pharmacovigilance + Asian ethnic-sensitivity considerations.
• Acceptable across product lifecycle — Reliance applies to new MAs, certain variations + license renewals.
• Asian ethnic-sensitivity assessment — Reliance Pathway typically requires Taiwan-specific or Asian bridging data for products with established Asian ethnic-sensitivity concerns; pharmacokinetic + pharmacodynamic considerations addressed via Taiwan + ICH E5 framework.
• ICH Regulatory Member status — Reliance Pathway is substantially reinforced by TFDA's ICH Regulatory Membership since 2018, providing TFDA with full ICH Working Group participation + ICH Step 4 / Step 5 implementation in Taiwan.
• Bilateral MoU support — TFDA bilateral MoUs with FDA, EMA, MHRA, Health Canada, TGA, Swissmedic, PMDA + MFDS facilitate reliance + information exchange.
• Asia-Pacific reach — Taiwan Reliance Pathway approvals are themselves accepted as reliance evidence by several smaller Asian regulators via bilateral arrangements with TFDA.
• Limitations — Reliance does not apply to controlled substances or certain Taiwan-specific products + full Taiwan assessment is required in those cases.
• Post-reliance variations follow the standard Variations framework — variation tiering applies to Reliance-approved products.

Taiwan's Medical Devices Act (醫療器材管理法) was enacted May 2020 + became effective May 2021 — separating medical-device regulation from the Pharmaceutical Affairs Act for the first time. The Act provides a modern medical-device regulatory framework substantively aligned with EU MDR, FDA QSR + IMDRF principles + has substantially modernised Taiwan's medical-device + IVD regulatory landscape.

• Class I — Lowest risk; TFDA Class I registration with reduced data requirements; certain Class I devices via simplified notification pathway.
• Class II — Moderate risk; substantively equivalent to EU MDR Class IIa / IIb with full technical + QMS evidence.
• Class III — Highest risk; substantively equivalent to EU MDR Class III with comprehensive clinical-evaluation + post-market surveillance requirements.
• IVD classification — Class I-III risk-based classification substantively aligned with IVDR principles with Taiwan-specific implementation.
• QMS Regulations — Taiwan medical-device QMS Regulations substantively aligned with ISO 13485:2016 + EU MDR QMS requirements; TFDA accepts ISO 13485:2016 certificates + MDSAP audit reports.
• Reference-regulator basis — TFDA recognises CE marking under EU MDR / IVDR, FDA 510(k) / De Novo / PMA, Health Canada, TGA + PMDA as evidence supporting Taiwan registration via device-equivalent of Reliance pathway.
• MDSAP recognition — TFDA accepts MDSAP audit reports as QMS evidence; full reliance for QMS-evidence purposes; TFDA is an MDSAP Affiliate Member.
• Taiwan License Holder — foreign manufacturers must designate a Taiwan-registered License Holder (similar to MAH role for drugs) who holds the establishment licence + handles regulatory interactions with TFDA + pharmacovigilance.
• Pharmaceutical Establishment Licence + Medical Device Establishment Licence — required for all Taiwan-resident manufacturers, importers + wholesalers; foreign manufacturers must operate through a Taiwan-licensed entity.
• Clinical evaluation — Class II + III typically require Taiwan clinical-investigation data or accepted reference-regulator clinical evidence with Asian ethnic-sensitivity overlay where relevant; Class I may use literature + comparator data.
• Field Safety Corrective Action (FSCA) — TFDA FSCA + Field Safety Notice (FSN) framework substantively aligned with EU MDR + IMDRF.
• Taiwan UDI — TFDA is progressively implementing UDI for medical devices following IMDRF UDI Guidance + with reference to FDA UDI + EU MDR UDI requirements.
• Software as Medical Device (SaMD) — Taiwan SaMD framework aligned with IMDRF SaMD Working Group outputs + with TFDA-specific guidance on AI / ML SaMD.

• Taiwan GMP — substantively aligned with PIC/S GMP Guide + ICH Q7 / Q9 / Q10; covers manufacture of medicinal products including biologics + APIs + medical devices.
• Taiwan GDP — Good Distribution Practice for drugs + medical devices; substantively aligned with PIC/S GDP Guide + EU GDP Guidelines.
• PIC/S Member since Jan 2013 — first PIC/S Member in the Greater China region; full GMP-inspection reliance with all PIC/S members.
• Reference Regulator network — TFDA recognises FDA, EMA + EU national, Health Canada, TGA, MHRA, Swissmedic, PMDA + MFDS as reference regulators for both product authorisation reliance + GMP-evidence reliance.
• Overseas inspections — TFDA conducts overseas inspections of foreign sites supplying Taiwan; risk-based programme prioritising new MA applications, biologics, sterile products + APIs; substantial expansion of overseas-inspection capacity since 2013.
• Data integrity — TFDA data-integrity expectations substantively aligned with PIC/S PI 041 + MHRA + WHO + FDA; ALCOA+ + audit-trail + computerised-systems requirements.
• MDSAP — TFDA accepts MDSAP audit reports as Taiwanese device QMS evidence; MDSAP Affiliate Member status with progressing recognition.
• Inspection findings + remediation — TFDA Inspection Reports + Suspension of Manufacturing / Importation + manufacturing-licence withdrawal; published market actions on TFDA portal.
• Pharmaceutical Establishment Licence — TFDA-issued licences for Taiwan-resident manufacturers, importers, wholesalers + retail pharmacies; required for all drug-handling activities + periodically renewed + inspected.
• Cross-Strait considerations — pharmaceutical + medical-device trade between Taiwan + Mainland China is governed by cross-Strait agreements + TFDA-NMPA technical cooperation, with substantial complexity due to political + regulatory considerations.
• Greater China leadership — TFDA's PIC/S Membership (since 2013, well ahead of NMPA + HKDH) + ICH Regulatory Membership (since 2018) make it a particularly influential regulator within the Greater China + Asia-Pacific landscape.

• TFDA Risk Management Office — TFDA pharmacovigilance unit operating Taiwan's national pharmacovigilance database; integrated with WHO VigiBase via UMC Uppsala.
• Taiwan National ADR Reporting Center (全國藥物不良反應通報中心) — central pharmacovigilance reporting facility under TFDA + CDE coordination.
• Taiwan pharmacovigilance Regulations — substantively aligned with ICH E2A / E2B / E2C / E2D / E2E + WHO GVP modules; covers ICSR + PSUR + RMP + signal detection.
• ICSR reporting — serious unexpected ADRs within 15 calendar days; non-serious in periodic reports + PSURs per ICH E2D + TFDA pharmacovigilance Regulations.
• PSUR — periodic safety update reports per ICH E2C(R2); harmonised with EU + ICH PSUR cycle; submitted to TFDA Risk Management Office.
• Risk Management Plan (RMP) — required for new active substances + biosimilars + significant indications; per ICH E2E + TFDA RMP guidance.
• Taiwan Pharmacovigilance Person (台灣藥物安全監視員) — Taiwan pharmacovigilance contact required for Taiwan MAH; substantively aligned with EU QPPV role.
• Pharmacovigilance Master File — equivalent to EU PSMF for new MAs + on-request inspection availability.
• Medical device vigilance — TFDA Medical Devices Act 2020 vigilance framework with FSCA + FSN substantively aligned with EU MDR vigilance + IMDRF.
• Healthcare-professional + consumer reporting — TFDA online reporting via dedicated TFDA portal + ADR Reporting Center channels.
• Recall — TFDA-coordinated recall framework with TFDA + Taiwan distributors + healthcare institutions + traceability support.
• Drug Shortages — TFDA drug-shortage monitoring programme; MAHs required to report shortages of essential medicines per National Health Insurance (NHI) reimbursement framework.
• TFDA Safety Communications — TFDA Safety Alerts + Notices published on TFDA portal + distributed to healthcare professionals + via Taiwan healthcare networks.

• PIC/S Member since Jan 2013 — first PIC/S Member in the Greater China region; full GMP-inspection reliance with all PIC/S members.
• ICH Regulatory Member since Jun 2018 — fifth Asian regulator with ICH Regulatory Member status; full ICH Working Group participation + Step 4 / Step 5 implementation.
• IMDRF Affiliate Member — active on UDI, SaMD, AI / ML, QMS work products + Taiwanese adoption of IMDRF outputs.
• MDSAP Affiliate Member — progressing toward fuller MDSAP recognition for Taiwanese device QMS purposes.
• APEC Regulatory Harmonization Steering Committee (RHSC) — active participant in APEC pharmaceutical + medical-device harmonisation; APEC LSIF Centers of Excellence (CoE) host institution.
• Asian Harmonization Working Party (AHWP) — TFDA founding + active member of AHWP for medical-device regulatory harmonisation across Asia-Pacific.
• ICMRA — active member contributing on pandemic preparedness, supply chain, regulatory innovation + reliance.
• Bilateral MoUs — TFDA holds MoUs with FDA, EMA, MHRA, Health Canada, TGA, Swissmedic, PMDA, MFDS, SFDA + many others; tight cooperation on inspections + safety + information exchange.
• Asia-Pacific reach — TFDA + CDE have substantial influence across Asia-Pacific through bilateral cooperation + Taiwanese product approvals are often accepted as reliance evidence by smaller Asian regulators.
• Cross-Strait technical cooperation — TFDA + NMPA technical cooperation on pharmaceutical + medical-device matters within the complex cross-Strait political + regulatory context.
• WHO collaboration — TFDA's WHO engagement is constrained by Taiwan's WHO observer status complications; TFDA participates in WHO technical fora through alternative arrangements + provides technical assistance via APEC + bilateral channels.

• Taiwan License Holder not properly established or scope mismatched — application rejected at TFDA intake or post-approval compliance failure.
• Pharmaceutical Establishment Licence + Medical Device Establishment Licence not in place — market placement blocked.
• Reliance Pathway eligibility misjudged — applicants applying for Reliance with non-designated reference regulator or incomplete reference dossier; clock reverts to full New Drug Application.
• Asian ethnic-sensitivity assessment gaps — applicants relying on foreign-only data for products with known Asian ethnic-sensitivity concerns; Taiwan or Asian bridging data required.
• Traditional Chinese-language labelling + IFU non-compliant — Taiwan labelling requires Traditional Chinese + specific TFDA-required content + warnings + Taiwan License Holder contact details.
• TFDA eCTD submission errors — module structure non-compliance, missing Module 1 Taiwan-specific elements, technical-format failures.
• CDE Consultation strategy not used — applicants failing to engage in pre-submission CDE Consultations (scientific advice) before submission; significantly higher rejection rate.
• Bioequivalence study quality issues — bioequivalence study at non-recognised centre or with methodology deficiencies; generic registration delayed or rejected.
• TFDA pharmacovigilance reporting timelines missed — Taiwan Pharmacovigilance Person enforcement.
• Data integrity findings — backdating, audit-trail disabled, shared logins, uncontrolled spreadsheets used as raw data; PIC/S + ICH-level expectations apply.
• Sterile / aseptic process gaps — TFDA inspectorate alignment with EU GMP Annex 1 (2022 revision) creates new expectations + frequent findings.
• MDSAP audit-report packaging gap — TFDA accepts MDSAP but requires the full audit report + non-conformity closures + Taiwan-specific QMS overlay.
• Medical Devices Act 2020 misunderstood — applicants treating device registration under pre-2021 Pharmaceutical Affairs Act framework rather than current Medical Devices Act framework.
• Clinical-trial CTA + Joint IRB coordination gap — Taiwan multi-site clinical trials require JIRB-coordinated review.
• PSUR not aligned with International Birth Date — Taiwan PSUR cycle out of sync with EMA PSUR / FDA PADER submissions.

V5 Ultimate provides the operational infrastructure Taiwanese + foreign-supplier sites need for Pharmaceutical Affairs Act + Medical Devices Act 2020 + TFDA Regulations + MOHW guidance compliance + TFDA readiness.

• TFDA GMP control framework — PIC/S-aligned controls (clean rooms, aseptic process, environmental monitoring, EU GMP Annex 1 2022 alignment, computerised systems) with ALCOA+ data-integrity + TFDA inspectorate alignment.
• Taiwan License Holder workflow — License Holder designation + scope management, Pharmaceutical Establishment + Medical Device Establishment Licence management, foreign-manufacturer QMS-evidence packaging.
• TFDA submission packaging — eCTD-aligned dossier structure with Taiwan Module 1 specifics, reference-regulator assessment-report packaging for Reliance Pathway.
• Reliance Pathway workflow — reference-regulator assessment-report packaging, designated-agency eligibility verification, Taiwan-specific overlay assessment with Asian ethnic-sensitivity considerations.
• Reference-regulator bridging — FDA / EMA / Health Canada / TGA / MHRA / Swissmedic / PMDA / MFDS assessment-report packaging for TFDA Reliance Pathway; Taiwan-specific data overlay.
• Medical Devices Act 2020 + IVD registration workflow — Class I-III + IVD classification, MDSAP + ISO 13485 audit-report packaging, TFDA Medical Devices Act framework tracking.
• CDE Consultation management — pre-submission CDE Consultation engagement workflow + Consultation Document packaging.
• Traditional Chinese + bilingual labelling + IFU — Traditional Chinese-language artwork workflow with two-person review + e-signature; TFDA-required elements + warnings + Taiwan License Holder details.
• TFDA pharmacovigilance — E2B(R3) ICSR generation, 15-day SUSAR timeline, PSUR / RMP packaging, Taiwan Pharmacovigilance Person workflow + Taiwan Pharmacovigilance Master File.
• Medical device vigilance — FSCA + FSN reporting per TFDA Medical Devices Act 2020 framework + IMDRF alignment.
• Asia-Pacific dual-market workflow — for companies operating across Taiwan + Korea + Japan + Singapore + ASEAN, V5 surfaces TFDA + MFDS + PMDA + HSA harmonised dossier-element reuse alongside national-specific extensions.
• National Health Insurance (NHI) coordination — for products targeting Taiwan public-sector reimbursement, V5 surfaces NHI listing workflow + reimbursement-package preparation.